ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
With reference to the captioned subject, this is to inform the exchange that the Company's joint venture, Aleor Dermaceuticals Limited has received US Food and Drug Administration (USFDA) Final Approval for Testosterone Topical Solution USP, 30 mg per pump actuation. Please find enclosed herewith our press release. We request you to kindly take the same on record. Alembic Pharmaceuticals Ltd - 533573 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform the exchange that the Company has issued Duplicate Share Certificate(s) to the registered shareholder(s) and / or their legal heir(s) on 15th June, 2021 as mentioned in the attached letter. We enclose herewith an intimation received from Link Intime India Private Limited, Registrar and Share Transfer Agent giving the proof of the date of receipt of aforesaid information by the Company. We request you to kindly take the same on record. ALEMBIC PHARMACEUTICALS LTD. - 533573 - Corporate Action - Fixes Book Closure For Payment Of Dividend And Annual General Meeting For The F.Y. 2020-21
Pursuant to Regulation 42 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform the exchange that the Register of Members and Share Transfer Books of the Company will remain closed from 21st July, 2021 to 27th July, 2021 (both days inclusive) for taking record of the Members of the Company for the purpose of payment of Dividend and Annual General Meeting of the Company for the F.Y. 2020-21. We request you to kindly take the same on your record and display the same on the website of the Stock Exchange. Alembic Pharmaceuticals Ltd - 533573 - Reg. 34 (1) Annual Report
Pursuant to Regulation 34 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith a copy of the Annual Report of the Company for the financial year ended 31st March, 2021. We request you to kindly take the same on record. Alembic Pharmaceuticals Ltd - 533573 - Notice Of 11Th Annual General Meeting Of The Members Of The Company Scheduled To Be Held On Tuesday, The 27Th July, 2021 At 3:00 P.M. IST Through Video Conferencing ('VC') / Other Audio Visual Means ('OAVM')
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith Notice of 11th Annual General Meeting of the Members of the Company scheduled to be held on Tuesday, the 27th July, 2021 at 3:00 p.m. IST through Video Conferencing ('VC') / Other Audio Visual Means ('OAVM'). We request you to kindly take the same on record. Alembic Pharmaceuticals Ltd - 533573 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform that the management of the Company has met / shall meet analyst(s) / investor(s) as per the details mentioned in the attached file. We request you to kindly take the same on record. Alembic Pharmaceuticals Ltd - 533573 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to Regulation 30 of the Listing Regulations, 2015, we enclose herewith a copy of the advance notice published in English and vernacular language (Gujarati) newspaper on 28th May, 2021 in Economic Times and Indian Express, English Edition and Financial Express Gujarati Edition, in compliance with Ministry of Corporate Affair's General Circular No. 20/2020 dated 5th May, 2020 inter alia informing the members that the 11th Annual General Meeting of the Company will be held on Tuesday, the 27th July, 2021 through Video Conferencing ('VC') / Other Audio Visual Means ('OAVM'). We request you to kindly take the same on record. Alembic Pharmaceuticals Ltd - 533573 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith a copy of advertisement related to notice of loss of share certificate(s) published by the Company on behalf of legal heir(s) of the registered shareholder(s) in English language newspaper - Business Standard on 27th May, 2021. We request you to kindly take the same on record.
Accumulate Alembic Pharmaceuticals; target of Rs 995: KR Choksey
KR Choksey recommended Accumulate rating on Alembic Pharmaceuticals with a target price of Rs 995 in its research report dated May 08, 2021.
Zydus & TLC sign pact to market drug 'Liposomal Amphotericin B' to treat black fungus in India
Separately, Alembic Pharma has also received Indian regulator (DCGI) nod to manufacture black fungus drug, Liposomal Amphotericin in Gujarat unit